Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.18
−$0.03 · -2.48%
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
Previous close
$1.18
−$0.03 · -2.48%
Regular session · ET · Market data may be delayed.
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
Day range
Current $1.18
52-week range
Current $1.18
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
65
Undervalued
Sentiment
56
Mixed
Risk
81
Extreme Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
Day range
Current $1.18
52-week range
Current $1.18
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.31M USD | 658K USD | — | — | — |
| Cost of goods sold | 3.96M USD | 1.24M USD | — | — | 747.65K USD |
| Gross profit | −2.65M USD | −580K USD | — | — | −747.65K USD |
| Research and development | 2.37M USD | 5.53M USD | 5.21M USD | 5.77M USD | 2.62M USD |
| Selling, general, and administrative | 2.52M USD | 2.53M USD | 4.51M USD | 5.3M USD | 7.42M USD |
| Operating expenses | 4.89M USD | 8.06M USD | 9.71M USD | 11.06M USD | 10.05M USD |
| Interest income | 20K USD | 100.47K USD | 3.92M USD | 3.05M USD | 928.76 USD |
| Interest expense | 359K USD | 1.44M USD | 3.8M USD | — | 3.36M USD |
| Depreciation and amortization | 1.42M USD | 1.65M USD | 514K USD | 562K USD | 471K USD |
| Operating income | −7.54M USD | −8.64M USD | −9.71M USD | −11.06M USD | −10.79M USD |
| Net income | −8.31M USD | 4.8M USD | −6.5M USD | −5.8M USD | −12.38M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 21, 2026 | 1:10 | — | — |
Stock split | May 21, 2024 | 1:10 | — | — |
Stock split | Nov 25, 2022 | 1:10 | — | — |
Effective Aug 21, 2026
1:10
Effective May 21, 2024
1:10
Effective Nov 25, 2022
1:10
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
